Liying Zhang

This inventor holds 16 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Immunotherapy Development. Top assignees: Pfizer Corporation, Rutgers, The State University of New Jersey. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liying Zhang. Retrieved from https://idiyas.com/inventor/liying-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 3)

% Patents Active = 68.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 34(Granted Patents)

Location History:

Malden, MA (US) (2017 - 2021)
Groton, CT (US) (2017 - 2021)
Lexington, MA (US) (2019 - 2021)
Belle Mead, NJ (US) (2014 - 2024)

Company Filing History:

Rutgers, The State University of New Jersey

patents

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Mesenchymal Stem Cells

Cytokines

Immunosuppression

RORC2 Modulators

Aminopyrimidinyl Compounds

Anti-Proliferative Agents

Immune Response

Pyrrolopyridine Compounds

Sulfonamide-Indole Compounds

Compositions

Treatment Methods

Biological Agents

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12156889 - Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression (2024-12-03),

2. 11872250 - Methods for inducing an immune response by administering activated mesenchymal stem cells (2024-01-16),

3. 11203594 - Anti-proliferative agents for treating PAH (2021-12-21),

4. 11197867 - Aminopyrimidinyl compounds (2021-12-14),

5. 10980815 - Aminopyrimidinyl compounds (2021-04-20),

6. 10898523 - Methods of producing activated mesenchymal stem cells (2021-01-26),

7. 10463675 - Aminopyrimidinyl compounds (2019-11-05),

8. 10426135 - Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2019-10-01),

9. 10385036 - Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof (2019-08-20),

10. 10336748 - Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2019-07-02),

11. 10227346 - Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof (2019-03-12),

12. 10046011 - Compositions for inducing or suppressing an immune response (2018-08-14),

13. 9670201 - Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2017-06-06),

14. 9663526 - Aminopyrimidinyl compounds (2017-05-30),

15. 9301979 - Method for attenuating immune response using mesenchymal stem cells and cytokines (2016-04-05),

Title: **Innovative Contributions of Liying Zhang in Pulmonary Hypertension Treatment**

Introduction

Liying Zhang, an accomplished inventor based in Malden, MA, has made significant strides in the field of pharmaceuticals with his impressive portfolio of 10 patents. His work primarily focuses on anti-proliferative agents and aminopyrimidinyl compounds, contributing to advancements in treating diseases such as pulmonary hypertension and cancer.

Latest Patents

Among Liying Zhang's latest patents is one related to anti-proliferative agents for treating pulmonary arterial hypertension (PAH). This invention encompasses compounds of general Formula I, their pharmaceutically acceptable salts, and the pharmaceutical compositions derived from them. The applications of these compounds extend to treating pulmonary hypertension and abnormal cell growth, including cancer.

Another significant patent includes aminopyrimidinyl compounds, featuring a detailed structure that offers various therapeutic possibilities. These compounds can act as Janus Kinase inhibitors, facilitating innovative treatment methodologies in pharmaceutical compositions, especially in combination with other therapeutic agents.

Career Highlights

Liying Zhang is currently associated with Pfizer Corporation, a leading company in the pharmaceutical industry. His role within the organization involves extensive research and development to bring groundbreaking treatments to market. His expertise in drug formulation and innovation has positioned him as a valuable asset to the company.

Collaborations

Throughout his career, Liying Zhang has collaborated with notable colleagues such as Li Huang Xing and Mark E. Schnute. These collaborations have enhanced his research and have led to synergistic developments, expanding the reach and impact of his innovative contributions in the field.

Conclusion

Liying Zhang's inventive spirit and dedication to research have resulted in crucial advancements in the treatment of serious health conditions. With his continued work in the pharmaceutical industry, he remains at the forefront of innovation, striving to improve patient outcomes through his patented inventions.

Profile summary based on public USPTO records.